### Philippines Tuberculosis Profile

**Population 2018**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td><strong>591 (332–924)</strong></td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td><strong>16 (4.1–19)</strong></td>
</tr>
<tr>
<td><strong>MDR-RR-TB incidence</strong></td>
<td><strong>16 (7.7–32)</strong></td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td><strong>26 (22–30)</strong></td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td><strong>0.6 (0.4–2.4)</strong></td>
</tr>
</tbody>
</table>

**Estimates of TB burden, 2018**

- **Total TB incidence**: 591 (332–924) (Rate: 554 (311–866))
- **HIV-positive TB incidence**: 16 (7.7–32)
- **HIV-negative TB mortality**: 26 (22–30)
- **HIV-positive TB mortality**: 0.6 (0.4–2.4)

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- **New cases**: 1.7% (1.1–2.5)
- **Previously treated cases**: 16% (19–20)

**TB case notifications, 2018**

- **Total new and relapse**: 371,668
  - % tested with rapid diagnostics at time of diagnosis: 36%
  - % with known HIV status: 27%
  - % pulmonary: 98%
  - % bacteriologically confirmed: 36%
  - % children aged 0-14 years: 12%
  - % women: 30%
  - % men: 58%
- **Total cases notified**: 382,543

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2018**: 63% (40–110)
- **TB patients facing catastrophic total costs, 2017**: 35% (33–37)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 5% (3–7)

**TB/HIV care in new and relapse TB patients, 2018**

- **Patients with known HIV status who are HIV-positive**: 1,477 (1%)
- **% on antiretroviral therapy**: 1,350 (91%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance:
  - **New cases**: <1%
  - **Previously treated cases**: 24%

**Laboratory-confirmed cases**

<table>
<thead>
<tr>
<th>Cases</th>
<th><strong>MDR/RR-TB</strong></th>
<th>XDR-TB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total cases tested for resistance to second-line drugs</strong>: 2,095</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patients started on treatment</strong></td>
<td>MDR/RR-TB: 7,276, XDR-TB: 52</td>
<td></td>
</tr>
<tr>
<td><strong>MDR/RR-TB cases tested for resistance to second-line drugs</strong></td>
<td>MDR/RR-TB: 6,125, XDR-TB: 52</td>
<td></td>
</tr>
</tbody>
</table>

**Treatment success rate and cohort size**

<table>
<thead>
<tr>
<th>Cases</th>
<th><strong>New and relapse cases registered in 2017</strong></th>
<th><strong>Previously treated cases, excluding relapse, registered in 2017</strong></th>
<th><strong>MDR-RR-TB cases started on second-line treatment in 2016</strong></th>
<th><strong>XDR-TB cases started on second-line treatment in 2016</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Success</strong></td>
<td>91%</td>
<td>82%</td>
<td>58%</td>
<td>20%</td>
</tr>
<tr>
<td><strong>Cohort</strong></td>
<td>315,923</td>
<td>9,486</td>
<td>1,258</td>
<td>10</td>
</tr>
</tbody>
</table>

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.7–10)

**TB financing, 2019**

<table>
<thead>
<tr>
<th>Cases</th>
<th><strong>National TB budget (US$ millions)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding source:</strong></td>
<td>12% domestic, 25% international, 63% unfunded</td>
</tr>
<tr>
<td><strong>Total budget (US$ millions):</strong></td>
<td>205</td>
</tr>
</tbody>
</table>

---

- **Ranges represent uncertainty intervals**
- **MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin**
- **Calculated for pulmonary cases only**
- **Includes cases with unknown previous TB treatment history**
- **Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed**

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-20

Data: www.who.int/tb/data